Datopotamab deruxtecan clinical trials
Also written Dato-DXd and DS-1062a.
ClinicalTrials.gov finds 51 studies for datopotamab deruxtecan. How that becomes 39 here
Every study that search finds has been read, apart from the 1 newest, to see whether and how it gives datopotamab deruxtecan. ClinicalTrials.gov counts as of Nov 17, 2026. How drug pages count
- 51Found by its intervention search · See all 51 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 42 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +3Give it under a name that search misses: a biosimilar’s code or a misspelling
- 54Give datopotamab deruxtecan to participants
- −3Observe patients on it, or give it outside a trial
- −12Give it beside what is tested
- 39Test it: the count on this site
Get an email when these change. Save the datopotamab deruxtecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Jan 2025 · DATROWAY · BLA 761394 (FDA, Drugs@FDA)
- European Union
- 4 Apr 2025 · Datroway · EMEA/H/C/006547 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
39 studies that test it; most in 2022 (7)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 6 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 29 · Other 10
AstraZeneca (21) · Daiichi Sankyo (7) · Gustave Roussy, Cancer Campus, Grand Paris (2) · Medical University of Vienna (1) · Daiichi Sankyo Co., Ltd. (1) · Fudan University (1) · UNC Lineberger Comprehensive Cancer Center (1) · Ana C Garrido-Castro, MD (1)
Often tested with
Tested in the same studies.
Carboplatin (6) · Durvalumab (5) · Rilvegostomig (5) · Cisplatin (4) · Trastuzumab deruxtecan (3) · Pemetrexed (3) · Ado-Trastuzumab Emtansine (2) · Pembrolizumab (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 5 most studied
New when their studies opened, with datopotamab deruxtecan beside them; studies of each.
- 1AZD5305
- 1Isuventatug
- 1GB268
- 1Palacaparib
- 1PRMT5 Inhibitor AZD3470
Reaching primary completion within a year · 6, 4 in phase 3
Studies that test datopotamab deruxtecan, phase 3 first.
- Jan 2027A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 3 · AstraZeneca
- Jul 2027A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)Phase 3 · AstraZeneca
- Sep 2027A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Phase 3 · AstraZeneca
- Nov 2027Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsPhase 3 · AstraZeneca
- Sep 2027Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerPhase 2 · Fudan University
- Oct 2027Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)Phase 2 · AstraZeneca
Studies
Open first, then newest update. How each study uses datopotamab deruxtecan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 39
- A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCNot yet recruitingPhase 2AstraZenecaNCT07941609Written as Dato-DXdReport a problem
- PREDICT-RD: ctDNA Surveillance in TNBC With Residual DiseaseRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07069595On ctDNA relapse in residual triple-negative diseaseWritten as Datopotamab deruxtecanReport a problem
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsRecruitingPhase 3AstraZenecaNCT07291037Against docetaxel in TROP2-positive lung cancerWritten as Datopotamab deruxtecan (Dato-DXd)Report a problem
- Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsRecruitingPhase 3AstraZenecaNCT06357533With rilvegostomig against pembrolizumab (TROPION-Lung10)Written as Datopotamab DeruxtecanReport a problem
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingPhase 1/2Daiichi SankyoNCT07890714With other drugs in solid tumours (TROPION-PanTumor04)Written as Dato-DXdReport a problem
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Added to durvalumab and chemotherapy before surgery in one armWritten as Dato-DXdReport a problem
- A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2AstraZenecaNCT07098338With ramucirumab, with or without rilvegostomig, in one sub-studyWritten as Dato-DXdReport a problem
- A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerRecruitingPhase 3AstraZenecaNCT07205822In HR-positive, HER2 IHC 0 breast cancerWritten as Dato-DXdReport a problem
- A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingPhase 3AstraZenecaNCT06103864With or without durvalumab first line (TROPION-Breast05)Written as Dato-DXdReport a problem
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)RecruitingPhase 2AstraZenecaNCT05489211Alone and with other drugs (TROPION-PanTumor03)Written as Datopotamab deruxtecan (Dato-DXd)Report a problem
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753One protein-matched ADCWritten as Datopotamab deruxtecan (Dato-DXd)Report a problem
- TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdRecruitingPhase 2Ana C Garrido-Castro, MDNCT06533826Sequenced with T-DXd after an ADC (TRADE-DXd)Written as Datopotamab DeruxtecanReport a problem
- Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 3AstraZenecaNCT06350097Added to first-line osimertinib (TROPION-Lung14)Written as Datopotamab DeruxtecanReport a problem
- A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)RecruitingPhase 2Latin American Cooperative Oncology GroupNCT06822543With carboplatin and pembrolizumabWritten as Datopotamab deruxtecanReport a problem
- Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaRecruitingPhase 2/3Daiichi SankyoNCT07129993With platinum against gemcitabine and platinumWritten as Dato-DXdReport a problem
- DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEsRecruitingPhase 2Nancy Lin, MDNCT06176261In breast cancer brain metastases (DATO-BASE)Written as Datopotamab DeruxtecanReport a problem
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingPhase 3AstraZenecaNCT07720284With rilvegostomig against standard careWritten as Dato-DXdReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Alone or with durvalumab in I-SPY arms before surgeryWritten as Datopotamab deruxtecanReport a problem
- A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast CancerRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT06508216Alone or with durvalumab in early-relapse triple-negative diseaseWritten as Dato-DXdReport a problem
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2AstraZenecaNCT03742102With durvalumab in one arm (BEGONIA)Written as Datopotamab deruxtecanReport a problem
See all 39 studies that test datopotamab deruxtecan →
Behind its US label · 4 — the studies the FDA label of DATROWAY describes
From the Clinical Studies section of DATROWAY (2026-05), as openFDA has it. A study the site does not hold is left out.
- Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)CompletedPhase 2Daiichi SankyoNCT04484142Report a problem
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)Active, not recruitingPhase 3Daiichi SankyoNCT04656652Report a problem
- A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)Active, not recruitingPhase 3AstraZenecaNCT05104866Report a problem
- A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)Active, not recruitingPhase 3AstraZenecaNCT05374512Report a problem
Tested on its own · 12 — no other medicine in its arm
- PREDICT-RD: ctDNA Surveillance in TNBC With Residual DiseaseRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07069595On ctDNA relapse in residual triple-negative diseaseWritten as Datopotamab deruxtecanReport a problem
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsRecruitingPhase 3AstraZenecaNCT07291037Against docetaxel in TROP2-positive lung cancerWritten as Datopotamab deruxtecan (Dato-DXd)Report a problem
- A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerRecruitingPhase 3AstraZenecaNCT07205822In HR-positive, HER2 IHC 0 breast cancerWritten as Dato-DXdReport a problem
- DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEsRecruitingPhase 2Nancy Lin, MDNCT06176261In breast cancer brain metastases (DATO-BASE)Written as Datopotamab DeruxtecanReport a problem
- Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung CancerActive, not recruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT04940325Alone in advanced lung cancerWritten as DS-1062aReport a problem
- Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain MetastasesActive, not recruitingPhase 2Medical University of ViennaNCT05866432In triple-negative breast cancer brain metastasesWritten as Datopotamab deruxtecanReport a problem
- A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)Active, not recruitingPhase 1/2AstraZenecaNCT05460273In Chinese patientsWritten as Datopotamab Deruxtecan (Dato-DXd)Report a problem
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)Active, not recruitingPhase 3Daiichi SankyoNCT04656652On the US labelAgainst docetaxel in lung cancer (TROPION-Lung01)Written as DS-1062aReport a problem
- A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)Active, not recruitingPhase 3AstraZenecaNCT05104866On the US labelAgainst chemotherapy in HR-positive breast cancer (TROPION-Breast01)Written as Dato-DXdReport a problem
- A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)Active, not recruitingPhase 3AstraZenecaNCT05374512On the US labelAgainst chemotherapy in triple-negative breast cancer (TROPION-Breast02)Written as Dato-DXdReport a problem
- Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)CompletedPhase 2Daiichi SankyoNCT04484142On the US labelIn lung cancer with actionable alterations (TROPION-Lung05)Written as DS-1062aReport a problem
- Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain MetastasesWithdrawnPhase 2MedSIRNCT06676917In lung cancer with active brain metastasesWritten as Datopotamab deruxtecanReport a problem
Tested with established drugs · 10 — they are given beside it
- A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCNot yet recruitingPhase 2AstraZenecaNCT07941609Written as Dato-DXdReport a problem
- A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2AstraZenecaNCT07098338With ramucirumab, with or without rilvegostomig, in one sub-studyWritten as Dato-DXdReport a problem
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)RecruitingPhase 2AstraZenecaNCT05489211Alone and with other drugs (TROPION-PanTumor03)Written as Datopotamab deruxtecan (Dato-DXd)Report a problem
- Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 3AstraZenecaNCT06350097Added to first-line osimertinib (TROPION-Lung14)Written as Datopotamab DeruxtecanReport a problem
- Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaRecruitingPhase 2/3Daiichi SankyoNCT07129993With platinum against gemcitabine and platinumWritten as Dato-DXdReport a problem
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerActive, not recruitingPhase 3AstraZenecaNCT06112379With durvalumab before surgery, against pembrolizumab (TROPION-Breast04)Written as Dato-DXdReport a problem
- Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsActive, not recruitingPhase 3AstraZenecaNCT05687266With durvalumab and carboplatin against pembrolizumab (AVANZAR)Written as Datopotamab deruxtecanReport a problem
- Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsActive, not recruitingPhase 3Daiichi SankyoNCT05215340Added to pembrolizumab first line (TROPION-Lung08)Written as Datopotamab DeruxtecanReport a problem
- First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)Active, not recruitingPhase 1Daiichi Sankyo Co., Ltd.NCT03401385First-in-human (TROPION-PanTumor01)Written as Datopotamab Deruxtecan (Dato-DXd)Report a problem
- Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)Active, not recruitingPhase 1Daiichi SankyoNCT04526691With pembrolizumab, with or without platinum (TROPION-Lung02)Written as Datopotamab deruxtecanReport a problem
Tested in a combination · 17 — another drug in the study is under test too
- Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsRecruitingPhase 3AstraZenecaNCT06357533With rilvegostomig against pembrolizumab (TROPION-Lung10)Written as Datopotamab DeruxtecanReport a problem
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingPhase 1/2Daiichi SankyoNCT07890714With other drugs in solid tumours (TROPION-PanTumor04)Written as Dato-DXdReport a problem
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Added to durvalumab and chemotherapy before surgery in one armWritten as Dato-DXdReport a problem
- A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingPhase 3AstraZenecaNCT06103864With or without durvalumab first line (TROPION-Breast05)Written as Dato-DXdReport a problem
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753One protein-matched ADCWritten as Datopotamab deruxtecan (Dato-DXd)Report a problem
- TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdRecruitingPhase 2Ana C Garrido-Castro, MDNCT06533826Sequenced with T-DXd after an ADC (TRADE-DXd)Written as Datopotamab DeruxtecanReport a problem
- A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)RecruitingPhase 2Latin American Cooperative Oncology GroupNCT06822543With carboplatin and pembrolizumabWritten as Datopotamab deruxtecanReport a problem
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingPhase 3AstraZenecaNCT07720284With rilvegostomig against standard careWritten as Dato-DXdReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Alone or with durvalumab in I-SPY arms before surgeryWritten as Datopotamab deruxtecanReport a problem
- A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast CancerRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT06508216Alone or with durvalumab in early-relapse triple-negative diseaseWritten as Dato-DXdReport a problem
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2AstraZenecaNCT03742102With durvalumab in one arm (BEGONIA)Written as Datopotamab deruxtecanReport a problem
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)Active, not recruitingPhase 3Daiichi SankyoNCT05555732With pembrolizumab, with or without platinum (TROPION-Lung07)Written as Datopotamab DeruxtecanReport a problem
- Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 1AstraZenecaNCT04612751With durvalumab, with or without carboplatin (TROPION-Lung04)Written as Datopotamab deruxtecanReport a problem
- A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 3AstraZenecaNCT06417814With or without osimertinib against chemotherapy (TROPION-Lung15)Written as Dato-DXdReport a problem
- A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Active, not recruitingPhase 3AstraZenecaNCT05629585With or without durvalumab after surgery (TROPION-Breast03)Written as Dato-DXdReport a problem
- A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesActive, not recruitingPhase 3AstraZenecaNCT06564844With rilvegostomig after surgery (TROPION-Lung12)Written as Datopotamab DeruxtecanReport a problem
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingPhase 2AstraZenecaNCT03944772With osimertinib in one module after progression (ORCHARD)Written as Datopotamab deruxtecanReport a problem
Beside an established treatment under test · 1 — an approved drug, surgery or radiation is what the study tests
Tested with datopotamab deruxtecan: durvalumab 1
- Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerRecruitingPhase 2Queen Mary University of LondonNCT06954480In every armEvery arm takes it while durvalumab is addedWritten as Datopotamab Deruxtecan (Dato-DXd)Report a problem
Beside a new treatment under test · 7 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with datopotamab deruxtecan: AZD5305 1 · isuventatug 1 · GB268 1 · palacaparib 1 · PRMT5 Inhibitor AZD3470 1
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesRecruitingPhase 1/2AstraZenecaNCT05417594Partner of new AZD9574 in one moduleWritten as Datopotamab Deruxtecan (Dato-DXd)Report a problem
- A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid TumorsRecruitingPhase 1/2AstraZenecaNCT06130553Partner of new AZD3470 in one moduleWritten as Datopotamab deruxtecanReport a problem
- GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)Not yet recruitingPhase 1/2Eddingpharm (Zhuhai) Co., Ltd.NCT07738341Partner of new GB268 in one armWritten as Datopotamab Deruxtecan (Dato-DXd)Report a problem
- A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07535437Partner of new ivonescimab in one cohortWritten as Dato-DXdReport a problem
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingPhase 1/2AstraZenecaNCT04644068Partner of new saruparib in one moduleWritten as Dato-DXdReport a problem
- A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid TumorsActive, not recruitingPhase 1Daiichi SankyoNCT06244485Partner of new valemetostatWritten as Dato-DXdReport a problem
- A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid TumorsActive, not recruitingPhase 1Cullinan Therapeutics Inc.NCT05117476Partner of new CLN-619 in one moduleWritten as Datopotamab deruxtecan-dlnk (Dato-DXd)Report a problem
Beside supportive care · 4 — a supportive treatment or test is studied
- SCALp Cooling for pReventing aLopecia With nEw anTibody-drug ConjugatesRecruitingPhase 2Jules Bordet InstituteNCT07474558One ADC while scalp cooling against hair loss is testedReport a problem
- An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.RecruitingPhase 4AstraZenecaNCT07357597In every armTreatment while stomatitis prophylaxis is testedWritten as Datopotamab Deruxtecan (Dato-DXd)Report a problem
- Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT07471776One ADC while TROP2 PET is testedReport a problem
- Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DMRecruitingPhase 2Brown UniversityNCT06974604Treatment while dexamethasone mouthwash prevents stomatitisReport a problem
Observed · 3 — patients on it are followed, or it is given outside a trial
- TROPION Breast Respond in 1L TNBCNot yet recruitingDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyNCT07867470First-line triple-negative breast cancer, observedWritten as Dato-DXdReport a problem
- Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic ResponseRecruitingFundación Pública Andaluza para la Investigación Biomédica Andalucía OrientalNCT07582887Genetic variants and ADC toxicity, observedWritten as Datopotamab DeruxtecanReport a problem
- Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC PatientsApproved for marketingDaiichi SankyoNCT06279728Medical access in EGFR-mutated lung cancerWritten as Datopotamab deruxtecanReport a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
Codes
What other systems call datopotamab deruxtecan · ClinicalTrials.gg INT002176
- MeSH (NLM) C000731951datopotamab deruxtecanOne source NLM
- UNII (FDA) GD2OWY1DTKDATOPOTAMAB DERUXTECANConfirmed FDA, NLM
- NCI Thesaurus C151967Datopotamab DeruxtecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731951 | datopotamab deruxtecan | One source NLM |
| UNII (FDA) | GD2OWY1DTK | DATOPOTAMAB DERUXTECAN | Confirmed FDA, NLM |
| NCI Thesaurus | C151967 | Datopotamab Deruxtecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.